Current issue #20, 2017

The immune drug era may replace the antibiotic era

There are two troubles in Russia: the dominance of immunomodulators, and a stronghold of their opponents. The exaggeration on both poles is likely to be a result of the systemic healthcare problems. On the one hand, no substantial evidence base has been accumulated yet, but, despite this fact, the drugs are registered. On the other hand, physicians that deny these drugs the right to existence have not been properly trained. However, immunologists do not give up as they believe the time of immune drugs is yet to come.

[PharmVestnik # 20, 13/06/2017, p. 6]

Moscow and Mexico to exchange public health development experience

On June 5^th, a memorandum of cooperation in healthcare was signed between Moscow and Mexico. The signatories noted a similarity of the problem scope and public health development courses of the two capitals, and apparent benefits of experience exchange.

[PharmVestnik # 20, 13/06/2017, p. 7]

Nanotechnologies may help in cancer management

Russian scientists offered certain R&D results in the field of applied medical nanotechnologies aimed at reducing side effects of cancer treatment. On June 1^st, scientists of Moscow Institute of Steel and Alloys, a national research technology institute, presented a nano encapsulated delivery system for chemotherapeutic agents along with tumor margin marking, and therapeutic implants.

[PharmVestnik # 20, 13/06/2017, p. 8]

Officials and medical manufacturers considered new medical device registration regulations

Within the framework of a special workshop on medical device registration in the light of new EAEU legislation (June 8, Moscow), officials of the Federal Service for Surveillance in Healthcare and ...